Travere Therapeutics, Inc.
pegtibatinase
Classical Homocystinuria (HCU)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews pegtibatinase for Classical Homocystinuria (HCU) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“The trial is expected to enroll approximately 70 patients aged 12 to 65 with a diagnosis of classical HCU and tHcy levels ≥50 µM while maintaining their standard-of-care treatment.”